Would you give doxorubicin and cisplatin for localized chondroblastic osteosarcoma in a patient with prior childhood anthracycline exposure and resultant cardiomyopathy with EF 50%?  

The risk:benefit ratio of a rechallenge with doxorubicin under the cover of dexrazoxane, especially for a curable new malignancy, should be acceptable and worth a cautious trial.

I think this commentary should help people not be afraid of doxorubicin, esp with a curable disease. Benjamin and Minotti, PMID 33990361 

This patient is clearly at higher risk of developing anthracycline associated cardiomyopathy with abnormal EF and prior anthracycline exposure. If this is recurrent OS, the patient has probably already received a fairly high dose of anthracycline. Risk of cardiomyopathy is certainly dose-related. At...